

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/054675-2025>

Tender

Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

NHS England

F02: Contract notice

Notice identifier: 2025/S 000-054675

Procurement identifier (OCID): ocds-h6vhtk-0595dd

Published 8 September 2025, 2:23pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Contact

Jessica Gaucher-Thompson

Email

jessica.gaucher-thompson@nhs.net

Country

United Kingdom

Region code

UKJ1 - Berkshire, Buckinghamshire and Oxfordshire

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://health-family.force.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://health-family.force.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England Specialised Commissioning (referred to as the Authority) is inviting suitably qualified and experienced providers to express interest in the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults) by responding to this accreditation process.

As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of five (5) years with the Commissioners having the option to extend for up to an additional four (4) year(s) (maximum contract duration nine (9) years).

The deadline for submissions is 12.00pm (noon) on Monday 13th October 2025.

II.1.5) Estimated total value

Value excluding VAT: £142,512,000

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The key objective of this procurement is to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients. Initially, this will be for the provision of Lifileucel for previously treated unresectable or metastatic melanoma. Services will be commissioned across seven (7) geographical regions to serve the population of England, as outlined below:

Lot 1: London

Lot 2: East of England

Lot 3: South East

Lot 4: South West

Lot 5: Midlands

Lot 6: North East and Yorkshire

Lot 7: North West

Bidders are to note:

- Providers may only bid for one Lot.
- There is no restriction on the number of sites that may be commissioned.
- Providers must be located in and deliver services from the geographical area(s) they are bidding to serve. that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.

Link to NHS England Regions:

NHS England » Regional teams(<https://www.england.nhs.uk/about/regional-area-teams/>).

The commissioner reserves the right to expand the scope of the contract during its term to include the delivery of additional TIL therapies to treat the same or similar conditions/indications, should they become available and deemed appropriate for inclusion.

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously

treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in early 2026.

Link for the current NICE paperwork:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the current specification, and any future reiterations below: <https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdf>

Providers must also;

- Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made.
- Hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.
- Have expertise in delivering and managing cellular therapies
- Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.
- Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation with accreditation being in place before contracts are awarded.
- Have experience relevant to Haematopoietic Stem Cell Transplantation.

Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.

To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal <https://health-family.force.com/s/Welcome> Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:

Phone: 08000988201

E-mail: support-health@atamis.co.uk

The closing date for completed Competitive Process responses is 12:00pm (noon), on Monday 13th October 2025.

Atamis Project reference C385818.

The contract duration is for five (5) years with the Commissioners having the option to extend for up to an additional four (4) year(s) (maximum contract duration nine (9) years).

This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract

is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £142,512,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

104

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

The contract duration is for five (5) years with the Commissioners having the option to extend for up to an additional four (4) year(s) (maximum contract duration nine (9) years).

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

13 October 2025

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 13 October 2026

IV.2.7) Conditions for opening of tenders

Date

13 October 2025

Local time

12:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

NHS Arden and Greater East Midlands Commissioning Support Unit

Cardinal Square, 10 Nottingham Road

Derby

DE1 3QT

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>